Q1 2025 Ionis Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Ionis Pharmaceuticals Inc (IONS) raised its 2025 financial guidance, reflecting confidence in its strategic execution and recent successful licensing transactions.
- The company achieved a major milestone with the successful commercial launch of TRYNGOLZA, the first FDA-approved treatment for familial chylomicronemia syndrome, exceeding expectations with over $6 million in net product sales in the first quarter.
- Ionis Pharmaceuticals Inc (IONS) is on track for multiple upcoming product launches, including donidalorsen for hereditary angioedema, which is expected to launch in the third quarter.
- The company reported a 10% year-over-year increase in revenue for the first quarter, with more than half of the revenue coming from commercial products, marking the first time in its history to report product revenue.
- Ionis Pharmaceuticals Inc (IONS) has a strong pipeline with upcoming Phase III data readouts for olezarsen and zilganersen, which could expand the reach of its medicines to more patients and drive long-term growth.
- The rapidly evolving environment, including changes at the FDA and new tariff policies, introduces uncertainty and potential disruption in the industry.
- Despite the successful launch of TRYNGOLZA, the vast majority of the estimated 3,000 people living with FCS in the US remain unidentified, indicating a need for continued patient finding efforts.
- The company faces challenges in converting patients from existing therapies to donidalorsen, as the hereditary angioedema market is competitive and requires significant patient and physician engagement.
- Ionis Pharmaceuticals Inc (IONS) anticipates high single-digit percentage increases in operating expenses for 2025, driven by investments in ongoing and planned product launches.
- The company acknowledges that the acute pancreatitis (AP) data from its sHTG studies is a secondary endpoint and not powered for AP, which may impact the ability to demonstrate significant reductions in AP events.
Good morning, and welcome to the Ionis first quarter 2025 financial results conference call. As a reminder, this call is being recorded.
At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin.
Thank you, Amy. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables that we will be discussing today, including a reconciliation of our GAAP to non-GAAP financials.
We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides on our website that accompany today's call. With me this morning are Brett Monia, our Chief Executive Officer; Kyle Jenne, Chief Global Product Strategy Officer; and Beth Hougen, Chief Financial Officer.
Richard Geary, Chief Development Officer; Eugene Schneider, Chief Clinical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
